key: cord-0946630-ak2k2g1m
authors: Hatziantoniou, Sophia; Anastassopoulou, Cleo; Lampropoulou, Vicky; Maltezou, Helena C.; Andreakos, Evangelos; Poland, Gregory A.; Tsakris, Athanasios
title: Comparative assessment of allergic reactions to COVID‐19 vaccines in Europe and the United States
date: 2022-02-24
journal: Allergy
DOI: 10.1111/all.15257
sha: d3ab4dc9125e6440478b65c26084d9d4f3bc573d
doc_id: 946630
cord_uid: ak2k2g1m

nan

To the Editor, Among the rare complications that may compromise vaccine acceptance are allergic reactions. [1] [2] [3] Recently, we demonstrated that anaphylaxis rates associated with COVID-19 vaccines are within the range of those observed earlier with other vaccines, as indicated by passive reporting systems. 4 Herein, we aimed to comparatively assess the incidence and potential underlying causes of the most com- The most common allergic reactions after COVID-19 vaccination were anaphylactic reactions, with an overall incidence of 9.91/million doses (EEA: 13.69/million/US: 4.44/million, Figure 1 ). Anaphylactic shock followed, with much lower rates (overall incidence: 1.36/million, EEA: 2.01/million/US: 0.41/million). Other allergic symptoms post vaccination, which were infrequently reported in the two databases, included, among others, "anaphylactoid reactions" and "al- Higher anaphylactic reaction rates have been reported after the first than the second dose, especially when prior anaphylaxis was present, but that was not always the case. 5, 6 The incidence of anaphylactic reactions reported in EudraVigilance varied considerably by vaccine and was threefold to fourfold higher for BNT162b2 or mRNA-1273 compared with VAERS. AD26.COV2.S-associated anaphylaxis did not differ between databases. The very low incidence of anaphylactic shock also varied by vaccine, particularly as captured in EudraVigilance.

Considering vaccine platforms, the incidence of anaphylactic reactions post adenovirus-vectored vaccination was higher compared with mRNA-based vaccines (EudraVigilance: 15.62/ vs. 13.36/million and VAERS: 6.79/ vs. 4.34/million doses). Anaphylactic shock incidence rates were also higher for vectored compared with mRNA vaccines (EudraVigilance: 3.14/ vs. 1.81/million and VAERS: 1.20/ vs. 0.38).

Detailed demographic data and outcomes of anaphylactic reaction and anaphylactic shock cases post-COVID-19 vaccination are presented in Tables S1 and S2, respectively. The vast majority of cases affected females (82% of anaphylactic reaction/75% of anaphylactic shock reports). The reasons why women have been implicated more frequently in hypersensitivity reactions throughout cohorts remain unknown.

With regard to age, different patterns are evident. In EudraVigilance, both types of anaphylaxis were more common among working age (18-64 years) and older individuals; in VAERS, anaphylactic reactions were more frequent among subjects aged 30-59 years (69%), while the very rare anaphylactic shock cases were distributed across age groups.

Regarding outcome, the vast majority of cases were resolved or resolving (90.0% of anaphylactic reaction/81.7% of anaphylactic | 1631 LETTERS shock cases as captured in EudraVigilance, Table S1 ). The disease course was complicated (life threatening or leading to permanent disability) in 25.5% of anaphylactic reaction and 31.3% of anaphylactic shock cases as captured in VAERS (Table S2) . Fatalities from allergic reactions post-COVID-19 vaccination were extremely rare and twofold to sixfold higher for vectored than mRNA vaccines in both databases ( Table 1 ).

The anaphylactic reactions and anaphylactic shock cases reported to EudraVigilance compared with VAERS indicated significant differences to exist between reporting systems, vaccine platforms, and manufacturers. Conceivably, the reported variability may reflect population differences in the degree of sensitization to ingredients prior to vaccination and differences in the prevalence of atopy, which has been linked to anaphylactic incidents post vaccination. 2, 7 Differences in implementation between the two reporting systems could also contribute to the observed differences between databases.

The cause(s) that may trigger allergic reactions after vaccination remain elusive. 2 Potential contributing factors include the following:

(i) components of the final pharmaceutical product (i.e., the active ingredient and excipients); (ii) impurities or "related materials" unintentionally present in the final formula; 1 and (iii) the packaging material, especially the rubber stopper. 2 Cross-reactivity has been reported upon exposure between two of the main excipients of mRNA and vectored vaccines (polyethylene glycol 2000 and polysorbate 80, respectively). 8 If true, should we anticipate increased anaphylaxis rates following first time or booster vaccination with vaccines of different platforms according to the so-called heterologous vaccination (mixand-match) approach?

A potential limitation of the study may be the likely underreporting of allergic reactions, including anaphylaxis that generally holds for passive surveillance systems; nonetheless, this may not hold for COVID-19 vaccines that have been under scrutiny by regulators and under the watchful eyes of healthcare professionals and the public since the beginning of their deployment. Other potential limitations, also related to passive reporting systems, entail possible reporting errors (e.g., duplicate or incomplete records), as well as the fact that recorded events only show temporal and not cause-effect relationships. In addition, the terminology used for the categorization of anaphylaxis post vaccination possibly introduces mechanistical explanations that may not be accurate. Nevertheless, for anaphylaxis and Guillain-Barré syndrome, the sensitivity of VAERS was found to be comparable to previous estimates for detecting important adverse events following vaccination. 9 Our pragmatic analysis is based on imperfect, but real-world data of two of the world's largest and most reliable vaccine adverse event Relevant investigations in the literature report contradictory results, concluding on higher anaphylaxis incidence for mRNA-1273 7 or BNT162b2. 5 These results emphasize the influence of the chosen datasets on the final conclusion.

Our study revealed differences in anaphylaxis rates as captured in two of the world's largest pharmacovigilance databases between Europe and the United States, as well as between vaccines and vaccine platforms. Understanding the reasons behind true differences could lead to the further optimization of COVID-19 vaccines. = 0.117, odds ratio = 2.58, 95% confidence interval = 1.14-5.83;

Anaphylactic reactions to mRNA COVID-19 vaccines: a call for further study

Vaccines and allergic reactions: the past, the current COVID-19 pandemic, and future perspectives

Vaccine-associated hypersensitivity

Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines

Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis

Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US

acute allergic reactions to mRNA COVID-19 vaccines

Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized

The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome

Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data

Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/ Food Allergy and Anaphylaxis Network Symposium